{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:06:36Z","timestamp":1790665596541,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T00:00:00Z","timestamp":1483488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T00:00:00Z","timestamp":1483488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/leu.2016.395","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T09:48:18Z","timestamp":1483523298000},"page":"1905-1914","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions"],"prefix":"10.1038","volume":"31","author":[{"given":"Y-J","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S E","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Screaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D E","family":"Spaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,4]]},"reference":[{"key":"BFleu2016395_CR1","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-14-1889","volume":"20","author":"FT Awan","year":"2014","unstructured":"Awan FT, Byrd JC . New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. Clin Cancer Res 2014; 20: 5869\u20135874.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016395_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646\u2013674.","journal-title":"Cell"},{"key":"BFleu2016395_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1746-1596-3-16","volume":"3","author":"JL Frater","year":"2008","unstructured":"Frater JL, Kay NE, Goolsby CL, Crawford SE, Dewald GW, Peterson LC . Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence. Diagn Pathol 2008; 3: 16.","journal-title":"Diagn Pathol"},{"key":"BFleu2016395_CR4","doi-asserted-by":"publisher","first-page":"13949","DOI":"10.3390\/ijms131113949","volume":"13","author":"CJ Yeom","year":"2012","unstructured":"Yeom CJ, Goto Y, Zhu Y, Hiraoka M, Harada H . Microenvironments and cellular characteristics in the micro tumor cords of malignant solid tumors. Int J Mol Sci 2012; 13: 13949\u20131365.","journal-title":"Int J Mol Sci"},{"key":"BFleu2016395_CR5","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/leu.2014.10","volume":"28","author":"M Masoodi","year":"2014","unstructured":"Masoodi M, Lee E, Eiden M, Bahlo A, Shi Y, Ceddia RB et al. A role for oleoylethanolamide in chronic lymphocytic leukemia. Leukemia 2014; 28: 1381\u20131387.","journal-title":"Leukemia"},{"key":"BFleu2016395_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1182\/blood-2013-03-489468","volume":"122","author":"S Tung","year":"2013","unstructured":"Tung S, Shi Y, Wong K, Zhu F, Gorczynski R, Laister RC et al. PPARalpha and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood 2013; 122: 969\u2013980.","journal-title":"Blood"},{"key":"BFleu2016395_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/leu.2012.329","volume":"27","author":"DE Spaner","year":"2013","unstructured":"Spaner DE, Lee E, Shi Y, Wen F, Li Y, Tung S et al. PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia 2013; 27: 1090\u20131099.","journal-title":"Leukemia"},{"key":"BFleu2016395_CR8","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1021\/cr2001355","volume":"111","author":"GS Harmon","year":"2011","unstructured":"Harmon GS, Lam MT, Glass CK . PPARs and lipid ligands in inflammation and metabolism. Chem Rev 2011; 111: 6321\u20136340.","journal-title":"Chem Rev"},{"key":"BFleu2016395_CR9","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1038\/oncsis.2016.41","volume":"5","author":"X Wang","year":"2016","unstructured":"Wang X, Wang G, Shi Y, Sun L, Gorczynski R, Li YJ et al. PPAR-delta promotes survival of breast cancer cells in harsh metabolic conditions. Oncogenesis 2016; 5: e232.","journal-title":"Oncogenesis"},{"key":"BFleu2016395_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/1471-2164-13-665","volume":"13","author":"C Khozoie","year":"2012","unstructured":"Khozoie C, Borland MG, Zhu B, Baek S, John S, Hager GL et al. Analysis of the peroxisome proliferator-activated receptor-beta\/delta (PPARbeta\/delta) cistrome reveals novel co-regulatory role of ATF4. BMC Genomics 2012; 13: 665.","journal-title":"BMC Genomics"},{"key":"BFleu2016395_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.cell.2008.06.051","volume":"134","author":"VA Narkar","year":"2008","unstructured":"Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008; 134: 405\u2013415.","journal-title":"Cell"},{"key":"BFleu2016395_CR12","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.2882","volume":"18","author":"K Ito","year":"2012","unstructured":"Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE et al. A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med 2012; 18: 1350\u20131358.","journal-title":"Nat Med"},{"key":"BFleu2016395_CR13","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1182\/blood-2010-05-285999","volume":"117","author":"J Tomic","year":"2011","unstructured":"Tomic J, Lichty B, Spaner DE . Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood 2011; 117: 2668\u20132680.","journal-title":"Blood"},{"key":"BFleu2016395_CR14","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","volume":"128","author":"S Oppermann","year":"2016","unstructured":"Oppermann S, Ylanko J, Shi Y, Hariharan S, Oakes CC, Brauer PM et al. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood 2016; 128: 934\u2013947.","journal-title":"Blood"},{"key":"BFleu2016395_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1084\/jem.20091663","volume":"207","author":"SE Dunn","year":"2010","unstructured":"Dunn SE, Bhat R, Straus DS, Sobel RA, Axtell R, Johnson A et al. Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med 2010; 207: 1599\u20131608.","journal-title":"J Exp Med"},{"key":"BFleu2016395_CR16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995; 57: 289\u2013300.","journal-title":"J R Stat Soc"},{"key":"BFleu2016395_CR17","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Bene MC et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010; 28: 2529\u20132537.","journal-title":"J Clin Oncol"},{"key":"BFleu2016395_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1476-5586(04)80047-2","volume":"6","author":"DR Rhodes","year":"2004","unstructured":"Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1\u20136.","journal-title":"Neoplasia"},{"key":"BFleu2016395_CR19","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/JCO.2004.12.133","volume":"22","author":"C Haslinger","year":"2004","unstructured":"Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut N et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004; 22: 3937\u20133949.","journal-title":"J Clin Oncol"},{"key":"BFleu2016395_CR20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/gcc.20579","volume":"47","author":"S Fabris","year":"2008","unstructured":"Fabris S, Mosca L, Todoerti K, Cutrona G, Lionetti M, Intini D et al. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 2008; 47: 781\u2013793.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu2016395_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.exphem.2005.05.007","volume":"33","author":"S Falt","year":"2005","unstructured":"Falt S, Merup M, Gahrton G, Lambert B, Wennborg A . Identification of progression markers in B-CLL by gene expression profiling. Exp Hematol 2005; 33: 883\u2013893.","journal-title":"Exp Hematol"},{"key":"BFleu2016395_CR22","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1182\/blood-2009-06-229211","volume":"114","author":"R Visone","year":"2009","unstructured":"Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114: 3872\u20133879.","journal-title":"Blood"},{"key":"BFleu2016395_CR23","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2014-12-618678","volume":"126","author":"Y Li","year":"2015","unstructured":"Li Y, Shi Y, McCaw L, Li YJ, Zhu F, Gorczynski R et al. Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17\/19A. Blood 2015; 126: 766\u2013778.","journal-title":"Blood"},{"key":"BFleu2016395_CR24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.18632\/oncotarget.129","volume":"1","author":"Y Pekarsky","year":"2010","unstructured":"Pekarsky Y, Croce CM . Is miR-29 an oncogene or tumor suppressor in CLL? Oncotarget 2010; 1: 224\u2013227.","journal-title":"Oncotarget"},{"key":"BFleu2016395_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ejh.12550","volume":"96","author":"S Molica","year":"2015","unstructured":"Molica S, Giannarelli D, Mirabelli R, Levato L, Russo A, Linardi M et al. Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model. Eur J Haematol 2015; 96: 72\u201377.","journal-title":"Eur J Haematol"},{"key":"BFleu2016395_CR26","doi-asserted-by":"crossref","first-page":"72608","DOI":"10.18632\/oncotarget.11618","volume":"7","author":"S Oppermann","year":"2016","unstructured":"Oppermann S, Lam AJ, Tung S, Shi Y, McCaw L, Wang G et al. Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. Oncotarget 2016; 7: 72608\u201372621.","journal-title":"Oncotarget"},{"key":"BFleu2016395_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563\u2013574.","journal-title":"Blood"},{"key":"BFleu2016395_CR28","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2009-09-245811","volume":"116","author":"AJ Steele","year":"2010","unstructured":"Steele AJ, Prentice AG, Cwynarski K, Hoffbrand AV, Hart SM, Lowdell MW et al. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin 4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood 2010; 116: 4569\u20134577.","journal-title":"Blood"},{"key":"BFleu2016395_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ccr.2007.07.012","volume":"12","author":"JW Shay","year":"2007","unstructured":"Shay JW, Wright WE . Tissue culture as a hostile environment: identifying conditions for breast cancer progression studies. Cancer Cell 2007; 12: 100\u2013101.","journal-title":"Cancer Cell"},{"key":"BFleu2016395_CR30","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.bbrc.2007.01.092","volume":"354","author":"E Hondares","year":"2007","unstructured":"Hondares E, Pineda-Torra I, Iglesias R, Staels B, Villarroya F, Giralt M . PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in muscle. Biochem Biophys Res Commun 2007; 354: 1021\u20131027.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu2016395_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jmb.2005.03.060","volume":"349","author":"TW Dunlop","year":"2005","unstructured":"Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C . The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol 2005; 349: 248\u2013260.","journal-title":"J Mol Biol"},{"key":"BFleu2016395_CR32","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1038\/jid.2008.32","volume":"128","author":"N al Yacoub","year":"2008","unstructured":"al Yacoub N, Romanowska M, Krauss S, Schweiger S, Foerster J . PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 2008; 128: 1940\u20131949.","journal-title":"J Invest Dermatol"},{"key":"BFleu2016395_CR33","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1021\/jm2017122","volume":"55","author":"S Lieber","year":"2012","unstructured":"Lieber S, Scheer F, Meissner W, Naruhn S, Adhikary T, Muller-Brusselbach S et al. DG172: an orally bioavailable PPARbeta\/delta-selective ligand with inverse agonistic properties. J Med Chem 2012; 55: 2858\u20132868.","journal-title":"J Med Chem"},{"key":"BFleu2016395_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2249.2009.04003.x","volume":"158","author":"SP Shaha","year":"2009","unstructured":"Shaha SP, Tomic J, Shi Y, Pham T, Mero P, White D et al. Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells. Clin Exp Immunol 2009; 158: 186\u2013198.","journal-title":"Clin Exp Immunol"},{"key":"BFleu2016395_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1749-6632.2000.tb06199.x","volume":"899","author":"DR Spitz","year":"2000","unstructured":"Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ . Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci 2000; 899: 349\u2013362.","journal-title":"Ann N Y Acad Sci"},{"key":"BFleu2016395_CR36","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1515\/hsz-2013-0215","volume":"394","author":"S Aleshin","year":"2013","unstructured":"Aleshin S, Reiser G . Role of the peroxisome proliferator-activated receptors (PPAR)-alpha, beta\/delta and gamma triad in regulation of reactive oxygen species signaling in brain. Biol Chem 2013; 394: 1553\u20131570.","journal-title":"Biol Chem"},{"key":"BFleu2016395_CR37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/CIRCRESAHA.109.206185","volume":"106","author":"P Wang","year":"2010","unstructured":"Wang P, Liu J, Li Y, Wu S, Luo J, Yang H et al. Peroxisome proliferator-activated receptor delta is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart. Circ Res 2010; 106: 911\u2013919.","journal-title":"Circ Res"},{"key":"BFleu2016395_CR38","doi-asserted-by":"publisher","first-page":"6042162","DOI":"10.1155\/2016\/6042162","volume":"2016","author":"L Fang","year":"2016","unstructured":"Fang L, Zhang M, Li Y, Liu Y, Cui Q, Wang N . PPARgene: a database of experimentally verified and computationally predicted PPAR target genes. PPAR Res 2016; 2016: 6042162.","journal-title":"PPAR Res"},{"key":"BFleu2016395_CR39","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1523\/JNEUROSCI.18-14-05112.1998","volume":"18","author":"SE Farinelli","year":"1998","unstructured":"Farinelli SE, Greene LA, Friedman WJ . Neuroprotective actions of dipyridamole on cultured CNS neurons. J Neurosci 1998; 18: 5112\u20135123.","journal-title":"J Neurosci"},{"key":"BFleu2016395_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0014-5793(03)00235-7","volume":"540","author":"B Halliwell","year":"2003","unstructured":"Halliwell B . Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett 2003; 540: 3\u20136.","journal-title":"FEBS Lett"},{"key":"BFleu2016395_CR41","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1101\/gad.178434.111","volume":"25","author":"Z Gan","year":"2011","unstructured":"Gan Z, Burkart-Hartman EM, Han DH, Finck B, Leone TC, Smith EY et al. The nuclear receptor PPARbeta\/delta programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes Dev 2011; 25: 2619\u20132630.","journal-title":"Genes Dev"},{"key":"BFleu2016395_CR42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1172\/JCI38942","volume":"120","author":"I Samudio","year":"2010","unstructured":"Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010; 120: 142\u2013156.","journal-title":"J Clin Invest"},{"key":"BFleu2016395_CR43","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/sj.leu.2405058","volume":"22","author":"CP Pallasch","year":"2008","unstructured":"Pallasch CP, Schwamb J, Konigs S, Schulz A, Debey S, Kofler D et al. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia 2008; 22: 585\u2013592.","journal-title":"Leukemia"},{"key":"BFleu2016395_CR44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cmet.2011.12.009","volume":"15","author":"A Le","year":"2012","unstructured":"Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012; 15: 110\u2013121.","journal-title":"Cell Metab"},{"key":"BFleu2016395_CR45","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0014-5793(99)01525-2","volume":"462","author":"SS Korshunov","year":"1999","unstructured":"Korshunov SS, Krasnikov BF, Pereverzev MO, Skulachev VP . The antioxidant functions of cytochrome c. FEBS Lett 1999; 462: 192\u2013198.","journal-title":"FEBS Lett"},{"key":"BFleu2016395_CR46","doi-asserted-by":"publisher","first-page":"9013","DOI":"10.1158\/0008-5472.CAN-07-1678","volume":"67","author":"F Lopez-Rios","year":"2007","unstructured":"Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, Ortega AD, Berrendero JR, Pozo-Rodriguez F et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 2007; 67: 9013\u20139017.","journal-title":"Cancer Res"},{"key":"BFleu2016395_CR47","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/nprot.2007.327","volume":"2","author":"P Mukhopadhyay","year":"2007","unstructured":"Mukhopadhyay P, Rajesh M, Hasko G, Hawkins BJ, Madesh M, Pacher P . Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat Protoc 2007; 2: 2295\u20132301.","journal-title":"Nat Protoc"},{"key":"BFleu2016395_CR48","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1210\/me.2007-0190","volume":"22","author":"BG Shearer","year":"2008","unstructured":"Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, Grillot DA et al. Identification and characterization of a selective peroxisome proliferator-activated receptor beta\/delta (NR1C2) antagonist. Mol Endocrinol 2008; 22: 523\u2013529.","journal-title":"Mol Endocrinol"},{"key":"BFleu2016395_CR49","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1124\/mol.111.074039","volume":"80","author":"S Naruhn","year":"2011","unstructured":"Naruhn S, Toth PM, Adhikary T, Kaddatz K, Pape V, Dorr S et al. High-affinity peroxisome proliferator-activated receptor beta\/delta-specific ligands with pure antagonistic or inverse agonistic properties. Mol Pharmacol 2011; 80: 828\u2013838.","journal-title":"Mol Pharmacol"},{"key":"BFleu2016395_CR50","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2119\/molmed.2015.00139","volume":"21","author":"D Messmer","year":"2015","unstructured":"Messmer D, Lorrain K, Stebbins K, Bravo Y, Stock N, Cabrera G et al. A selective novel peroxisome proliferator-activated receptor (PPAR)-alpha antagonist induces apoptosis and inhibits proliferation of CLL cells in vitro and in vivo. Mol Med 2015; 21: 410\u2013419.","journal-title":"Mol Med"},{"key":"BFleu2016395_CR51","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","volume":"126","author":"R Guieze","year":"2015","unstructured":"Guieze R, Wu CJ . Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood 2015; 126: 445\u2013453.","journal-title":"Blood"},{"key":"BFleu2016395_CR52","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3892\/ijmm.2016.2499","volume":"37","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Gu P, Shi W, Li J, Hao Q, Cao X et al. MicroRNA-29a induces insulin resistance by targeting PPARdelta in skeletal muscle cells. Int J Mol Med 2016; 37: 931\u2013938.","journal-title":"Int J Mol Med"},{"key":"BFleu2016395_CR53","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.molmed.2016.05.002","volume":"22","author":"S Menegon","year":"2016","unstructured":"Menegon S, Columbano A, Giordano S . The dual roles of NRF2 in cancer. Trends Mol Med 2016; 22: 578\u2013593.","journal-title":"Trends Mol Med"},{"key":"BFleu2016395_CR54","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bbadis.2015.02.010","volume":"1852","author":"E Barroso","year":"2015","unstructured":"Barroso E, Rodriguez-Rodriguez R, Chacon MR, Maymo-Masip E, Ferrer L, Salvado L et al. PPARbeta\/delta ameliorates fructose-induced insulin resistance in adipocytes by preventing Nrf2 activation. Biochim Biophys Acta 2015; 1852: 1049\u20131058.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu2016395_CR55","doi-asserted-by":"publisher","first-page":"12890","DOI":"10.1073\/pnas.0705505104","volume":"104","author":"A Abdollahi","year":"2007","unstructured":"Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA 2007; 104: 12890\u201312895.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016395_CR56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/nature17173","volume":"531","author":"S Beyaz","year":"2016","unstructured":"Beyaz S, Mana MD, Roper J, Kedrin D, Saadatpour A, Hong SJ et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature 2016; 531: 53\u201358.","journal-title":"Nature"},{"key":"BFleu2016395_CR57","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1096\/fj.14-264515","volume":"29","author":"F Mao","year":"2015","unstructured":"Mao F, Xu M, Zuo X, Yu J, Xu W, Moussalli MJ et al. 15-Lipoxygenase-1 suppression of colitis-associated colon cancer through inhibition of the IL-6\/STAT3 signaling pathway. FASEB J 2015; 29: 2359\u20132370.","journal-title":"FASEB J"},{"key":"BFleu2016395_CR58","doi-asserted-by":"publisher","first-page":"7084","DOI":"10.1073\/pnas.1324233111","volume":"111","author":"D Wang","year":"2014","unstructured":"Wang D, Fu L, Ning W, Guo L, Sun X, Dey SK et al. Peroxisome proliferator-activated receptor delta promotes colonic inflammation and tumor growth. Proc Natl Acad Sci USA 2014; 111: 7084\u20137089.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016395_CR59","doi-asserted-by":"publisher","first-page":"dju052","DOI":"10.1093\/jnci\/dju052","volume":"106","author":"X Zuo","year":"2014","unstructured":"Zuo X, Xu M, Yu J, Wu Y, Moussalli MJ, Manyam GC et al. Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-delta\/beta overexpression. J Natl Cancer Inst 2014; 106: dju052.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2016395_CR60","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc3214","volume":"12","author":"JM Peters","year":"2012","unstructured":"Peters JM, Shah YM, Gonzalez FJ . The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012; 12: 181\u2013195.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2016395_CR61","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1182\/blood-2010-11-318451","volume":"117","author":"C Pepper","year":"2011","unstructured":"Pepper C, Fegan C . CLL: a supplementary question? Blood 2011; 117: 1439\u20131440.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016395","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2016.395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T15:02:03Z","timestamp":1718982123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,4]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFleu2016395"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.395","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,4]]},"assertion":[{"value":"21 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}